Obesity is an epidemic that represents a public health c...
Próximas questões
Com base no mesmo assunto
Ano: 2026
Banca:
UFU-MG
Órgão:
UFU-MG
Prova:
UFU-MG - 2026 - UFU-MG - Vestibular - Segundo Semestre 2026 |
Q4200525
Inglês
Obesity is an epidemic that represents a public health challenge. According to the World Obesity Atlas
2025, the total number of adults living with obesity is expected to increase by more than 115% between 2010
and 2030, rising from 524 million to 1.13 billion. The scenario is even more concerning because most countries
worldwide lack sufficient plans and policies to address rising obesity levels.
It is in this context that the so-called “weight-loss pens” are gaining increasing traction. These are injectable medications that mimic the action of the intestinal hormone GLP-1 (and, in some cases, also GIP), increasing satiety and improving glycemic control. Initially developed for the treatment of type 2 diabetes, these drugs are also now among the main approved therapies for obesity treatment.
GLP-1 agonists are medications that mimic the action of the body’s natural hormone called GLP-1 (glucagon‐like peptide‐1), which plays a role in blood sugar control. They bind to receptors on cells – like fitting into a “lock” – and activate these receptors to produce effects similar to those the hormone itself would cause. This is the case with semaglutide.
Dual agonists work similarly but act on two different receptors simultaneously: in addition to GLP-1, they also act on GIP, an acronym for gastric inhibitory polypeptide. This is the case with tirzepatide, which acts on the brain and gastrointestinal tract to reduce appetite, increase satiety, and slow gastric emptying.
Although effective for weight loss, the rapid weight reduction promoted by these medications is not limited to the loss of body fat. Part of the weight lost can also come from lean mass, which is composed of muscles, bones, and organs.
Disponível em: https://myminerva.minervafoods.com. Acesso em: 9 dez. 2025.
Com base no texto, analise as asserções.
I. De acordo com o Atlas Mundial da Obesidade de 2025, estima-se que os índices de obesidade terão mais que o dobro do crescimento entre 2010 e 2030.
II. A maioria dos países possui estratégias e políticas eficazes para combater as crescentes taxas de obesidade.
III. As chamadas “canetas emagrecedoras” atuam na mimetização dos hormônios do intestino, tais como o GLP-1 e, em alguns casos, o GIP.
IV. Os agentes agonistas ou imitadores, tais como a tirzepatida, atuam em dois receptores hormonais simultaneamente.
V. A perda de peso causada por esses medicamentos impacta na diminuição da gordura corporal e não reduz a massa magra.
Assinale a alternativa que apresenta apenas asserções corretas.
It is in this context that the so-called “weight-loss pens” are gaining increasing traction. These are injectable medications that mimic the action of the intestinal hormone GLP-1 (and, in some cases, also GIP), increasing satiety and improving glycemic control. Initially developed for the treatment of type 2 diabetes, these drugs are also now among the main approved therapies for obesity treatment.
GLP-1 agonists are medications that mimic the action of the body’s natural hormone called GLP-1 (glucagon‐like peptide‐1), which plays a role in blood sugar control. They bind to receptors on cells – like fitting into a “lock” – and activate these receptors to produce effects similar to those the hormone itself would cause. This is the case with semaglutide.
Dual agonists work similarly but act on two different receptors simultaneously: in addition to GLP-1, they also act on GIP, an acronym for gastric inhibitory polypeptide. This is the case with tirzepatide, which acts on the brain and gastrointestinal tract to reduce appetite, increase satiety, and slow gastric emptying.
Although effective for weight loss, the rapid weight reduction promoted by these medications is not limited to the loss of body fat. Part of the weight lost can also come from lean mass, which is composed of muscles, bones, and organs.
Disponível em: https://myminerva.minervafoods.com. Acesso em: 9 dez. 2025.
Com base no texto, analise as asserções.
I. De acordo com o Atlas Mundial da Obesidade de 2025, estima-se que os índices de obesidade terão mais que o dobro do crescimento entre 2010 e 2030.
II. A maioria dos países possui estratégias e políticas eficazes para combater as crescentes taxas de obesidade.
III. As chamadas “canetas emagrecedoras” atuam na mimetização dos hormônios do intestino, tais como o GLP-1 e, em alguns casos, o GIP.
IV. Os agentes agonistas ou imitadores, tais como a tirzepatida, atuam em dois receptores hormonais simultaneamente.
V. A perda de peso causada por esses medicamentos impacta na diminuição da gordura corporal e não reduz a massa magra.
Assinale a alternativa que apresenta apenas asserções corretas.
Conheça nossos planos